GLPwatch
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
N Engl J Med · 2023
Last updated 2026-07-12| Journal | N Engl J Med, 2023 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.19 |
| NIH percentile | 12 |
| Molecules | orforglipron |
Full record and abstract on PubMed 38091543 ↗
Related research
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.